Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Bio-Path Holdings (BPTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Bio-Path: 1Q Earnings Snapshot

BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Thursday reported a loss of $1.5 million in its first quarter.

BPTH : 14.54 (-0.82%)
Bio-Path Holdings Reports First Quarter 2019 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 16, 2019 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 16, 2019 at 8:30 AM Eastern...

BPTH : 14.54 (-0.82%)
Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Biotech Brief: FDA Fast Tracking Innovative Breakthrough Therapies For Cancer Patients

A recent headline from a report released by Friends of Cancer Research, made the following eye-opening statement: "ONE OF THE BIGGEST TREATMENT BREAKTHROUGHS IN THE PAST FIVE YEARS WASN'T A DRUG, BUT A...

WVE : 25.41 (+5.04%)
ZSAN : 2.73 (-1.09%)
BPTH : 14.54 (-0.82%)
PFE : 41.95 (+0.07%)
MBRX : 1.11 (-0.89%)
Biotech Brief: Clinical Progress Leading to New Technological Developments for Arrhythmia Monitoring

A recent market research report from a well-respected industry source, Grand View Research, said that it expects the Arrhythmia Monitoring Devices Market to be worth $8.41 billion by 2025 with a CAGR of...

ABT : 76.98 (+1.79%)
BSX : 38.47 (+1.80%)
JNJ : 138.85 (-0.67%)
BSGM : 6.87 (-4.32%)
BPTH : 14.54 (-0.82%)
Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Medical Device Industry Revenues Should Outpace Healthcare Field

The U.S. markets are bullish on the future of the medical device markets. In addition to projections that postulate that: "In 2024, the total medical technology revenue globally is expected be nearly $600...

ALDX : 7.33 (+2.81%)
MHMNF : 54.5000 (unch)
ENDP : 5.95 (-2.78%)
ABBV : 80.06 (-1.34%)
BPTH : 14.54 (-0.82%)
SOLY : 5.73 (+4.95%)
Bio-Path Holdings Reports Full Year 2018 Financial Results

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Bio-Path Holdings, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 20, 2019 / Bio-Path Holdings, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 20, 2019 at 8:30 AM Eastern...

BPTH : 14.54 (-0.82%)
Estimated Revenues Continue to Rise for U.S. and Global Medical Device Markets

The U.S. medical device industry has seen its revenues continue to increase and it is poised is to become the global leader of this expanding market. It seems as though each new projection breaks through...

DERM : 9.95 (+2.37%)
ATOS : 2.60 (-0.38%)
BPTH : 14.54 (-0.82%)
AVGR : 0.46 (-3.19%)
SOLY : 5.73 (+4.95%)
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

Bio-Path Holdings, Inc. (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize(R) antisense RNAi nanoparticle technology to develop a portfolio of targeted...

BPTH : 14.54 (-0.82%)
Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize(R) antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid...

BPTH : 14.54 (-0.82%)
FDA Regulations Allow Medical Devices Clinical Trials to Differ From Pharmaceutical Trials

Clinical trials are the pathway for new drugs or devices to enter the U.S. and other worldwide markets. However, not all clinical trials are the same. A recent article by a 20+ year insider in the clinical...

ARQL : 7.53 (+2.59%)
LLY : 116.79 (-0.02%)
BPTH : 14.54 (-0.82%)
SOLY : 5.73 (+4.95%)
SEEL : 2.64 (unch)
Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with Excellent Patient Safety Profile

BPTH : 14.54 (-0.82%)
Thinking about buying stock in AmBev, Advanced Micro Devices, Bio-Path Holdings, The Gap or Weatherford International?

InvestorsObserver issues critical PriceWatch Alerts for ABEV, AMD, BPTH, GPS, and WFT.

WFT : 0.37 (unch)
AMD : 26.44 (+0.30%)
GPS : 21.46 (+0.94%)
ABEV : 4.26 (unch)
BPTH : 14.54 (-0.82%)
U.S. Medical Device Market Reaches $156 Billion Mark

Medical technology is an area where the U.S. companies are at the forefront. In fact, according to recent industry publication the: "U.S. remains the largest medical device market in the world, with a...

TGTX : 7.20 (+1.12%)
AMRN : 17.63 (+2.03%)
PBYI : 15.45 (+0.98%)
BPTH : 14.54 (-0.82%)
SOLY : 5.73 (+4.95%)
Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs,...

BPTH : 14.54 (-0.82%)
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)

DALLAS, TX / ACCESSWIRE / January 24, 2019 / Bio-Path Holdings, Inc. (NASDAQ: BPTH):

BPTH : 14.54 (-0.82%)

Van Meerten Stock Picks

NextEra Energy - Large Cap Pick
The Large Cap Pick of the Day is electric utility company NextEra Energy(NEE).
NEE -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar